RESUMO
Concomitant with the onset of S phase, a series of thymidine kinase (TK) splicing intermediates as well as mature TK mRNA accumulates in the nucleus of BALB/c 3T3 cells. Most of the TK splicing intermediates are retained by oligo(dT)-cellulose chromatography, and, therefore, 3' end formation and polyadenylation probably precede the splicing of TK pre-mRNAs. We have further characterized the TK pre-mRNAs that are present in the nuclei of S-phase cells by using specific probes derived from each of the six TK intervening sequences. Based on the sizes of the pre-mRNAs and their patterns of hybridization with these intron probes, we propose a pathway for intron removal from nascent TK transcripts. Intron excision occurred by a preferred, but not necessarily obligatory, order which appears to have been conserved in mouse and Chinese hamster cells.
Assuntos
Interfase , Splicing de RNA , Timidina Quinase/metabolismo , Animais , Northern Blotting , Núcleo Celular/metabolismo , Cricetinae , Cricetulus , Íntrons , Camundongos , Precursores de Ácido Nucleico/metabolismo , Fatores de TempoRESUMO
A novel cyclin gene was discovered by searching an expressed sequence tag database with a cyclin box profile. The human cyclin E2 gene encodes a 404-amino-acid protein that is most closely related to cyclin E. Cyclin E2 associates with Cdk2 in a functional kinase complex that is inhibited by both p27(Kip1) and p21(Cip1). The catalytic activity associated with cyclin E2 complexes is cell cycle regulated and peaks at the G1/S transition. Overexpression of cyclin E2 in mammalian cells accelerates G1, demonstrating that cyclin E2 may be rate limiting for G1 progression. Unlike cyclin E1, which is expressed in most proliferating normal and tumor cells, cyclin E2 levels were low to undetectable in nontransformed cells and increased significantly in tumor-derived cells. The discovery of a novel second cyclin E family member suggests that multiple unique cyclin E-CDK complexes regulate cell cycle progression.
Assuntos
Quinases relacionadas a CDC2 e CDC28 , Quinases Ciclina-Dependentes/metabolismo , Ciclinas/metabolismo , Proteínas Serina-Treonina Quinases/metabolismo , Sequência de Aminoácidos , Animais , Sequência de Bases , Catálise , Ciclo Celular , Linhagem Celular , Linhagem Celular Transformada , Clonagem Molecular , Quinase 2 Dependente de Ciclina , Ciclinas/genética , DNA Complementar , Fase G1 , Expressão Gênica , Humanos , Camundongos , Dados de Sequência Molecular , Homologia de Sequência de Aminoácidos , Células Tumorais CultivadasRESUMO
BRCA1 mRNA and protein levels are regulated by the steroid hormones estrogen and progesterone in human breast cancer cells. BRCA1 mRNA and protein levels were significantly decreased in estrogen-depleted MCF-7 and BT20T cells and increased again after stimulation with beta-estradiol. The increase in BRCA1 expression upon stimulation with estrogen was not coordinated with the early induction of the estrogen-dependent pS2 gene but closely paralleled the delayed increase in the S-phase dependent marker cyclin A. T47-D cells deprived of steroid hormones and subsequently stimulated with progesterone also showed a delayed increase in BRCA1 mRNA expression. However, no change in BRCA1 protein was detected in these cells. When considered together, the data suggest that steroid hormones may affect BRCA1 expression indirectly by altering the proliferative status of the cells rather than acting directly on DNA sequences in the BRCA1 gene itself.
Assuntos
Neoplasias da Mama/genética , Estradiol/farmacologia , Proteínas de Neoplasias/metabolismo , Proteínas , Fatores de Transcrição/metabolismo , Proteína BRCA1 , Ciclinas/metabolismo , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Técnicas In Vitro , Progesterona/farmacologia , RNA Neoplásico/genética , Receptores de Estrogênio/metabolismo , Receptores de Progesterona/metabolismo , Fator Trefoil-1 , Células Tumorais Cultivadas , Proteínas Supressoras de TumorRESUMO
We have determined that expression of the c-myb proto-oncogene is associated with estrogen receptor (ER) status and not with tumor progression in human breast epithelial cells. Analysis of normal, immortalized, nontumorigenic, and tumorigenic mammary epithelial cells showed that only ER+ tumor cell lines expressed readily detectable levels of c-myb mRNA and a Mr 75,000 protein that was the same size as the c-myb transcripts and protein products present in hematopoietic cells. In this report we show that c-myb mRNA and protein levels are down-regulated during estrogen withdrawal. A 20-fold increase in c-myb mRNA and protein expression was observed upon addition of beta-estradiol to the culture medium. Nuclear run-on transcription analyses showed that c-myb was transcribed at the same rate in the presence and absence of estrogen, suggesting that c-myb mRNA accumulation was regulated at a posttranscriptional level. To provide additional evidence that c-myb mRNA was dependent on ER expression, we examined c-myb mRNA levels in MCF-7 cells selected for resistance to antineoplastic drugs. c-myb expression was decreased only in cell lines that showed concomitant loss of ER expression. Moreover, c-myb mRNA was expressed and modulated by estrogen in ER-, MDA-MB-231 cells stably transfected with a human ER gene. When considered together, these data indicate that c-myb mRNA levels are regulated by estrogens and further suggest that this proto-oncogene plays a role in the biology of ER+ breast tumor cells.
Assuntos
Neoplasias da Mama/enzimologia , Regulação Neoplásica da Expressão Gênica , Oncogenes , Proteínas Proto-Oncogênicas/genética , Processamento Pós-Transcricional do RNA , Receptores de Estrogênio/fisiologia , Transativadores/genética , Transcrição Gênica , Mama/efeitos dos fármacos , Mama/metabolismo , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Núcleo Celular/metabolismo , Células Cultivadas , Estradiol/farmacologia , Feminino , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Proto-Oncogene Mas , Proteínas Proto-Oncogênicas/biossíntese , Proteínas Proto-Oncogênicas c-myb , Receptores de Estrogênio/genética , Proteínas Recombinantes/biossíntese , Transativadores/biossíntese , Transcrição Gênica/efeitos dos fármacos , Transfecção , Células Tumorais Cultivadas , Células U937RESUMO
The MDM2 gene is a nuclear phosphoprotein that is regulated by p53 and functions, in one capacity, to inhibit the transcriptional activity of the wild-type p53 protein. Multiple MDM2 transcripts were detected in human breast epithelial cells. In estrogen receptor-negative normal, immortal, and tumorigenic breast epithelial cells, we found a good correlation between MDM2 mRNA levels and expression of wild-type p53. When wild-type p53 was overexpressed in estrogen receptor-negative tumor cells containing a mutant or no endogenous p53, MDM2 mRNA levels increased significantly, indicating that wild-type p53 positively influences MDM2 mRNA levels in these tumor cells. Because all estrogen receptor-positive breast tumor cells had high MDM2 mRNA levels regardless of the status of their endogenous p53 protein, other factors likely influence MDM2 expression in these cells. Distinct MDM2 proteins (range, Mr 54,000-68,000 and 90,000-100,000, respectively) were differentially expressed in human breast epithelial cells. The lower molecular weight MDM2 proteins were most abundant in the normal mammary cells but present at varying levels in many of the tumor cells examined. MDM2 was a nuclear protein; however, nuclear staining intensity did not always correlate with the amount of MDM2-immunoreactive protein as determined by Western blot analysis. This discrepancy suggests that MDM2 interacts with novel cellular proteins in different kinds of breast epithelial cells.
Assuntos
Neoplasias da Mama/metabolismo , Mama/metabolismo , Regulação Neoplásica da Expressão Gênica , Proteínas Nucleares , Proteínas Proto-Oncogênicas/genética , Transcrição Gênica , Neoplasias da Mama/genética , Células Cultivadas , Células Epiteliais/metabolismo , Feminino , Genes p53 , Humanos , Imuno-Histoquímica , Proteínas de Neoplasias/genética , Proteínas Proto-Oncogênicas c-mdm2 , RNA Mensageiro/genética , Células Tumorais Cultivadas , Proteína Supressora de Tumor p53/genéticaRESUMO
The effects of a ligand of the aromatic hydrocarbon receptor (AhR), benzo[a] pyrene (B[ a]P), and its metabolite, BPDE (7r,8t-dihydroxy-9t,10t-epoxy-7,8,9,10-tetrahydro-benzo[a]pyrene), on BRCA-1 levels and cell cycle kinetics were determined in MCF-7 breast cancer cells. Exposure of asynchronous MCF-7 cells for 72 hours to a non-cytotoxic dose of 0.5 microM B[a]P triggered a three-fold reduction in BRCA-1 protein. In MCF-7 cells resistant (20% to 30%) to genotoxic concentrations of B[a]P (1 to 5 microM), the loss of BRCA-1 protein was coupled with pausing in S-phase and G2/M, and accumulation of p53, mdm2 and p21. Treatment of MCF-7 cells synchronized in S-phase (72%) with B[a]P prolonged the arrest in S-phase, although this checkpoint was transient since cells resumed to G2/M after 12 hours with reduced levels of BRCA-1. In these cells, levels of p53 were increased, whereas the cellular content of p21 remained unaltered. In contrast, the co-treatment with the AhR antagonist, alpha-naphthoflavone (ANF), abrogated the deleterious effects of B[a]P on BRCA-1 expression, while preventing the accumulation of p53 and disruption of cell cycle profile. These findings suggest that the AhR mediated the inverse expression patterns of BRCA-1 and p53 upon exposure to B[a]P. The treatment with BPDE induced S-phase arrest and reduced BRCA-1 mRNA levels. The negative effects of BPDE on BRCA-1 expression were not transient since removal of BPDE did not allow complete reversal of the repression. These cumulative data suggest that the B[a]P metabolite, BPDE, may play a key role in disruption of BRCA-1 expression and cell cycle kinetics in breast epithelial cells.
Assuntos
7,8-Di-Hidro-7,8-Di-Hidroxibenzo(a)pireno 9,10-óxido/farmacologia , Adenocarcinoma/patologia , Proteína BRCA1/biossíntese , Benzo(a)pireno/farmacologia , Neoplasias da Mama/patologia , Ciclo Celular/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Genes BRCA1 , Genes p53 , Proteínas de Neoplasias/biossíntese , Receptores de Hidrocarboneto Arílico/efeitos dos fármacos , Proteína Supressora de Tumor p53/biossíntese , Adenocarcinoma/genética , Afidicolina/farmacologia , Proteína BRCA1/genética , Benzoflavonas/farmacologia , Neoplasias da Mama/genética , Colchicina/farmacologia , Depressão Química , Relação Dose-Resposta a Droga , Feminino , Fase G2/efeitos dos fármacos , Humanos , Proteínas de Neoplasias/efeitos dos fármacos , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/fisiologia , Receptores de Hidrocarboneto Arílico/fisiologia , Fase S/efeitos dos fármacos , Células Tumorais Cultivadas/efeitos dos fármacos , Células Tumorais Cultivadas/metabolismoRESUMO
Little is known regarding the regulation of expression of the RHOA protooncogene, a member of the family of genes encoding Ras-related GTP-binding proteins. We have previously reported that the 3' untranslated region (UTR) of RHOA was contained within a genomic sequence which flanked the 5' end of the human glutathione peroxidase 1-encoding gene [J.A. Moscow et al., J. Biol. Chem. 267 (1992) 5949-5958]. Our previous studies revealed the presence of multiple (1.8 and 1.5 kb) RHOA mRNA species in breast cancer cell lines and of three putative polyadenylation signals in the RHOA 3' UTR. In this report, we have isolated several RHOA cDNAs from a multidrug-resistant MCF-7 human breast cancer cell line. Sequence analyses of these RHOA cDNA clones indicate that multiple polyadenylation signals are used to terminate RHOA transcripts. RNase-protection analysis demonstrated that all three polyadenylation signals are utilized in breast cancer cell lines and RNA stability studies demonstrated that RHOA RNA species with different 3' ends have equivalent stability. Since little is known about the RNA expression of RHOA in human tumors, and since both activated and non-activated RHOA genes possess transformation potential, we analyzed RHOA mRNA in lung and colon tumors by Northern blot and RNase-protection analyses. In all eight lung tumors examined, RHOA RNA levels were decreased relative to the level in normal surrounding tissue, whereas RHOA expression was decreased in only two of six colon tumors. We also found that lovastatin-induced cell cycle arrest resulted in increased RHOA RNA expression in breast cancer cell lines.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Proteínas de Ligação ao GTP/genética , Poli A/metabolismo , Proto-Oncogenes , Sequência de Bases , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Neoplasias do Colo/genética , Neoplasias do Colo/metabolismo , DNA Complementar , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Fígado/metabolismo , Lovastatina/farmacologia , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Dados de Sequência Molecular , Distribuição Tecidual , Células Tumorais Cultivadas , Proteína rhoA de Ligação ao GTPRESUMO
We have determined the molecular organization and transcription start points (tsp) for the murine gene (TK) encoding thymidine kinase. The exon/intron structure and sequences present at the splice junctions of the mammalian TK genes have been highly conserved; however, the promoter sequences of these genes have diverged widely. Both the human and Chinese hamster TK promoter regions contain CCAAT and TATA consensus motifs, whereas the mouse promoter has neither element. This difference between species is reflected in that, unlike the hamster and human TK genes, transcription initiates from numerous specific tsp within a 100-bp region in the mouse TK gene. The complex pattern of tsp seen in the endogenous gene was not maintained in transfected cell lines containing TK promoter::beta-globin (HBB) fusions. Transcription from the murine TK:HBB fusion genes initiated from a small number of tsp that were clustered downstream from the ATG in hybrids containing TK coding sequences, and in the HBB 5' UTR in hybrids that did not. Few or no specific tsp were detected from the upstream sites used in the endogenous mouse TK gene.
Assuntos
Regiões Promotoras Genéticas/genética , Timidina Quinase/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Clonagem Molecular , Cricetinae , Cricetulus , Éxons/genética , Globinas/genética , Humanos , Íntrons/genética , Dados de Sequência Molecular , Proteínas Recombinantes de Fusão/genética , Mapeamento por Restrição , Timidina Quinase/química , Transcrição Gênica/genéticaRESUMO
We describe two transfectable vectors designed to facilitate the functional analysis of eukaryotic promoter/enhancer sequences. The first, pJFCAT1, is an improved chloramphenicol acetyltransferase (CAT) reporter gene expression vector with two features that distinguish it from the majority of other CAT vectors currently in use: 1) it carries a trimer cassette of the simian virus 40 major late polyadenylation site to block plasmid-initiated read-through expression of CAT, and 2) it includes the phage f1 origin of replication, permitting generation of single-stranded copies to serve as templates for oligonucleotide-directed mutagenesis or single-strand DNA sequencing. The promoterless pJFCAT1 directs little if any CAT activity in transfected mouse L cells and, therefore, may be particularly useful for the analysis of weak promoters whose activity is otherwise masked by background CAT expression. The second vector, pTAG-1, uses human beta-globin as a reporter gene and was designed to facilitate the analysis of reporter gene expression at the RNA level. Like pJFCAT1, pTAG-1 also includes the simian virus 40 polyadenylation site trimer cassette located just upstream of the promoter insertion site. We have used each of these vectors to study functional elements in the human and mouse thymidine kinase promoters.
Assuntos
Elementos Facilitadores Genéticos/genética , Vetores Genéticos , Regiões Promotoras Genéticas/genética , Animais , Sequência de Bases , Northern Blotting , Cloranfenicol O-Acetiltransferase/biossíntese , Cloranfenicol O-Acetiltransferase/genética , Regulação da Expressão Gênica , Globinas/biossíntese , Globinas/genética , Humanos , Técnicas In Vitro , Camundongos , Dados de Sequência Molecular , Mutagênese Insercional , Plasmídeos , RNA/análise , Mapeamento por Restrição , TransfecçãoRESUMO
The induction of thymidine kinase mRNA has proved to be a valuable model for understanding regulatory events at the G1/S boundary of the cell cycle (1, 2, 3). As an initial step toward characterizing the regulation of this gene in Chinese hamster cells, I have mapped the transcription start sites for TK mRNA in CHEF/18 cells. Two closely spaced sites of transcription initiation were detected downstream of a nonconsensus TATAA element in the promoter region. Using primer extension analyses, I demonstrated that the transcription initiation sites remained constant while the absolute levels of TK mRNA varied during the cell cycle in synchronized populations of Chinese hamster cells.
Assuntos
Regulação Enzimológica da Expressão Gênica , RNA Mensageiro/genética , Timidina Quinase/genética , Transcrição Gênica , Animais , Sequência de Bases , Ciclo Celular , Linhagem Celular , Cricetinae , Cricetulus , Expressão Gênica , Cinética , Dados de Sequência Molecular , Peso Molecular , Oligodesoxirribonucleotídeos , Regiões Promotoras Genéticas , RNA Mensageiro/isolamento & purificação , RNA Mensageiro/metabolismo , TATA Box , TransfecçãoRESUMO
We have previously demonstrated that incubation of Hepa-1 cells in the presence of cytochalasin B (CB) results in a time- and temperature-dependent loss of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) binding activity (Gudas et al., 1986). We show here that this loss of binding activity is probably attributable to a CB induced inhibition of glucose transport, as incubation of cells in the presence of glycolytic inhibitors or in glucose free medium caused a similar effect. All conditions leading to loss of binding also caused a marked reduction in cellular ATP concentration, suggesting that ATP (or perhaps another energy-dependent molecule) is required for maintaining the receptor in the active state. Inactivation of the Ah receptor occurred in the cytosol but not when it had translocated to the nucleus. Reactivation of receptor binding activity occurred readily in vivo and did not require de novo protein synthesis. However, attempts to restore receptor binding activity in vitro were not successful. To our knowledge this is the first reported evidence indicating that the TCDD binding Ah receptor can exist in both an inactive and an active form, with the amount present in the active ligand binding form being coupled to the energy state of the cells.
Assuntos
Trifosfato de Adenosina/metabolismo , Dioxinas/metabolismo , Neoplasias Hepáticas Experimentais/metabolismo , Dibenzodioxinas Policloradas/metabolismo , Receptores de Droga/metabolismo , Animais , Citosol/metabolismo , Receptores de Hidrocarboneto ArílicoRESUMO
The induction of cytochrome P 450c mRNA and associated aryl hydrocarbon hydroxylase (AHH) activity is mediated by the Ah receptor in rodent liver and hepatic cells in vitro. In the present study we have investigated the underlying mechanisms responsible for the regulation of AHH activity in differentiated and dedifferentiated variants of the rat hepatoma cell line H4IIEC3. All of the dedifferentiated variants expressed inducible cytochrome P-450c mRNA and AHH activity following treatment with polycyclic aromatic hydrocarbons or the compound 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Most of the differentiated derivatives, however, were not inducible for either of these functions. Somatic cell hybridization studies revealed that the differentiated cells were AHH negative due to a defect that corresponded to the Ah receptor D gene product. 5-Azacytidine and sodium butyrate, but not mutagens, reactivated a functional Ah receptor in the differentiated line Fao, indicating that a requisite gene had been silenced by an epigenetic mechanism in this strain. Since many of the 5-azacytidine-induced revertant clones resembled dedifferentiated derivatives with respect to morphology and/or diminished expression of hepatic traits, our results support a correlation between coexpression of the dedifferentiated phenotype and AHH inducibility in these hepatoma cells.
Assuntos
Sistema Enzimático do Citocromo P-450/biossíntese , Neoplasias Hepáticas Experimentais/enzimologia , Receptores de Droga/genética , Animais , Hidrocarboneto de Aril Hidroxilases/biossíntese , Hidrocarboneto de Aril Hidroxilases/genética , Diferenciação Celular , Linhagem Celular , Sistema Enzimático do Citocromo P-450/genética , Indução Enzimática , Neoplasias Hepáticas Experimentais/genética , Neoplasias Hepáticas Experimentais/patologia , Fenótipo , Compostos Policíclicos/farmacologia , Ratos , Receptores de Hidrocarboneto Arílico , Receptores de Droga/análiseRESUMO
The posttranscriptional regulatory mechanism(s) underlying thymidine kinase (TK) mRNA accumulation was investigated in BALB/c 3T3 cells during their progression from G0 into S phase of the cell cycle. Very little TK mRNA could be detected in either the nuclear or the cytoplasmic compartment from cells harvested in G0 or G1. At the onset of S phase, however, the level of nuclear TK mRNA precursors and mature TK mRNAs increased dramatically. The high molecular weight TK heterogeneous nuclear RNA species detected in the nuclei of S-phase cells were polyadenylylated and hybridized to intron sequences derived from the TK gene. A series of high molecular weight precursors could be chased to lower molecular weight species in the presence of actinomycin D, suggesting an ordered removal of intron sequences with the kinetics of a precursor-product relationship. These results demonstrate a striking change in the nuclear posttranscriptional processing of TK heterogeneous nuclear RNA at the G1-S boundary and, furthermore, define a model system for the examination of RNA-processing events in vivo.
Assuntos
Núcleo Celular/metabolismo , Processamento Pós-Transcricional do RNA , RNA Nuclear Heterogêneo/metabolismo , Timidina Quinase/genética , Animais , Linhagem Celular , Citoplasma/metabolismo , Dactinomicina/farmacologia , Fibroblastos/metabolismo , Interfase , Íntrons , Camundongos , Camundongos Endogâmicos BALB C , Poli A/biossíntese , Precursores de RNA/metabolismo , Processamento Pós-Transcricional do RNA/efeitos dos fármacos , RNA Mensageiro/biossínteseRESUMO
The subcellular distribution of the Ah receptor from the mouse hepatoma line, Hepa-1, was investigated following cytochalasin B treatment and cell enucleation. Probing the resultant cytoplast and nucleoplast fractions with radiolabelled tetrachlorodibenzo-p-dioxin (TCDD) revealed the presence of a specifically bound peak of receptor only in the cytoplast fraction. However, the quantity of receptor recovered in these experiments was only 10-12% of the expected value. We therefore undertook an investigation to determine the fate of the Ah receptor in the presence of cytochalasin B. Incubation of Hepa-1 cells with this compound resulted in a rapid loss or inactivation of cytosolic binding activity with a concomitant decrease in the amount of receptor partitioned into the nucleus at all time periods examined. Control experiments indicated that cytochalasin B did not compete with TCDD for binding to the Ah receptor and furthermore, that its mechanism of action could not be attributed to a non-specific effect on all cytosolic proteins. The results obtained are discussed in relation to the proposed models for induction by the estrogen and glucocorticoid binding receptors.
Assuntos
Citosol/análise , Dioxinas/metabolismo , Neoplasias Hepáticas Experimentais/análise , Dibenzodioxinas Policloradas/metabolismo , Receptores de Droga/análise , Animais , Linhagem Celular , Cicloeximida/farmacologia , Citocalasina B/farmacologia , Glucosefosfato Desidrogenase/análise , Cinética , Neoplasias Hepáticas Experimentais/ultraestrutura , Camundongos , Receptores de Hidrocarboneto ArílicoRESUMO
Induction of thymidine kinase parallels the onset of DNA synthesis. To investigate the transcriptional regulation of the thymidine kinase gene, we have examined whether specific nuclear factors interact in a cell-cycle-dependent manner with sequences upstream of this gene. Two inverted CCAAT boxes near the transcriptional initiation sites were observed to form complexes with nuclear DNA-binding proteins. The nature of the complexes changes dramatically as the cells approach DNA synthesis and correlates well with the previously reported transcriptional increase of the thymidine kinase gene.
Assuntos
Ciclo Celular , Proteínas de Ligação a DNA/metabolismo , Proteínas Nucleares/metabolismo , Regiões Promotoras Genéticas , Timidina Quinase/genética , Sítios de Ligação , Ligação Competitiva , Replicação do DNA , Humanos , Oligonucleotídeos/metabolismo , Ligação Proteica , RNA Mensageiro/genética , Sequências Reguladoras de Ácido Nucleico , Transcrição GênicaRESUMO
We have isolated a new benzo(a)pyrene-resistant clone, c35, of the mouse hepatoma line, Hepa-1. Cytochrome P1-450 mRNA and P1-450-dependent aryl hydrocarbon hydroxylase (AHH) activity are no longer inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin in c35. The phenotype of c35 is unstable in long-term culture. A subclone, c35-1, having partially restored AHH inducibility, was studied in detail. The concentration of dioxin required to give half-maximal induction of AHH activity was 16-fold greater in c35-1 than in Hepa-1. Scatchard analysis showed that c35-1 contains reduced levels of the Ah (dioxin) receptor, which mediates induction of P1-450, but that the affinity of the receptor for dioxin is unaltered. In vivo assays confirmed that c35-1 possesses reduced levels of receptor but showed that it is even more severely affected in nuclear translocation of the receptor. Somatic cell hybridization experiments demonstrated that c35 is recessive and belongs to a new, third complementation group of mutants defective in Ah receptor activity. We propose that c35 is mutated either in the ligand-binding Ah receptor polypeptide or in another polypeptide required for receptor function and that in c35-1 partial reversion has occurred to generate a polypeptide which is still impaired in its role in promoting nuclear translocation and/or DNA binding.
Assuntos
Dioxinas/metabolismo , Genes , Dibenzodioxinas Policloradas/metabolismo , Receptores de Droga/genética , Animais , Hidrocarboneto de Aril Hidroxilases/biossíntese , Hidrocarboneto de Aril Hidroxilases/genética , Hidrocarboneto de Aril Hidroxilases/metabolismo , Linhagem Celular , Células Clonais , Sistema Enzimático do Citocromo P-450/genética , Sistema Enzimático do Citocromo P-450/metabolismo , Indução Enzimática , Cinética , Neoplasias Hepáticas Experimentais/metabolismo , Camundongos , Mutação , NADPH-Ferri-Hemoproteína Redutase/genética , NADPH-Ferri-Hemoproteína Redutase/metabolismo , Dibenzodioxinas Policloradas/farmacologia , RNA Mensageiro/genética , Receptores de Hidrocarboneto ArílicoRESUMO
In order to study the induction mechanism of aryl hydrocarbon hydroxylase (AHH), non-inducible mutants have previously been isolated from the mouse hepatoma cell line, Hepa-1. With the ultimate goal of isolating the corresponding genes, restoration of AHH inducibility to representative mutants by means of DNA-mediated gene transfer has been set out. The successful transfection of a C- mutant, which is defective in nuclear translocation of the Ah receptor-inducer complex, is described here, using rat genomic DNA as donor material. Primary and secondary rat transfectants were obtained, and they were assayed for hydroxylase activity, receptor translocation, and homology with a rat repetitive DNA sequence.
Assuntos
Hidrocarboneto de Aril Hidroxilases/genética , DNA/genética , Neoplasias Hepáticas Experimentais/genética , Receptores de Droga/genética , Animais , Hidrocarboneto de Aril Hidroxilases/biossíntese , Núcleo Celular/metabolismo , Indução Enzimática , Neoplasias Hepáticas Experimentais/metabolismo , Camundongos , Receptores de Hidrocarboneto Arílico , Receptores de Droga/metabolismo , Sequências Repetitivas de Ácido Nucleico , TransfecçãoRESUMO
We have used site-specific mutagenesis and thymidine kinase (TK) promoter/reporter gene transfection experiments to investigate DNA sequences required for serum-responsive regulation of expression from the mouse thymidine kinase promoter. Mutations were targeted to each of three previously described protein binding domains (MT1, MT2, and MT3) upstream of the TK translation initiation site, as well as to sequences within the TK first exon in order to address each of the following three questions: (a) Do these sequences play any role in regulation? (b) Do all of these sites play the same role? and (c) If any controls are observed, do they act positively or negatively on gene expression? The results of these experiments indicated that, in the wild-type TK promoter, at least some of these sequences do play a role in regulation, that not all of these sites appear to play the same role, and that some of the targeted elements act positively on gene expression, whereas others appear to act negatively. In particular, mutagenesis of the Sp1 site within MT1 virtually eliminated promoter function, whereas mutations in either the MT2 site or the TK first exon rendered reporter gene expression nearly constitutive with respect to serum. Thus, both MT2 and sequences within the TK first exon appear to contain negatively acting elements. In contrast, mutation or deletion of the MT3 site produced a much less pronounced effect on reporter gene regulation. These results support recent observations from our laboratory (Q-P. Dou et al., manuscript in preparation) indicating that although the protein complexes that bind to these various sites are similar, they are not identical.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Fenômenos Fisiológicos Sanguíneos , Regulação da Expressão Gênica/fisiologia , Genes Reporter , Regiões Promotoras Genéticas , Timidina Quinase/genética , Células 3T3 , Animais , Sequência de Bases , Camundongos , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Ligação Proteica , TransfecçãoRESUMO
In this study, we compare the expression patterns of p53 mRNA and protein in normal human mammary epithelial cells following synchronization to different points in the cell cycle using two independent methods. When treated with lovastatin, the cells were blocked in G1 and appeared to express increased levels of wild-type p53 when examined by immunostaining. Upon reversal of the metabolic block, the number of nuclei that stained positively for p53 declined dramatically during mid-G1 and increased again concomitant with the entry of cells into S phase. In contrast to the immunostaining results, Northern and Western blot analyses revealed little change in p53 mRNA and protein levels in the lovastatin-synchronized cells. When normal human mammary epithelial cells were made quiescent by removal of growth factors, the mRNA for p53 showed a biphasic distribution. p53 mRNA levels were increased during growth arrest, decreased during the G1 phase, and rose again concomitant with the entry of cells into S phase. The immunostaining pattern of p53 also showed a biphasic distribution similar to the pattern of mRNA expression. Despite an increase in p53 mRNA and immunostaining levels, growth factor-arrested cells actually had less total p53 protein. Upon stimulation to proliferate, p53 protein levels remained low throughout G1 and increased concomitant with the entry of cells into S phase. Taken together, the results from these studies demonstrate that p53 immunostaining patterns do not correlate with the overall levels of p53 protein at different times during the cell cycle. Therefore, the distinct changes observed in p53 immunostaining patterns are likely due to posttranslational modifications, conformational changes, or interactions of p53 with other cellular proteins during the cell cycle.
Assuntos
Mama/metabolismo , Proteína Supressora de Tumor p53/biossíntese , Mama/citologia , Mama/efeitos dos fármacos , Ciclo Celular/efeitos dos fármacos , Ciclo Celular/fisiologia , Células Cultivadas , Células Epiteliais , Epitélio/efeitos dos fármacos , Epitélio/metabolismo , Substâncias de Crescimento/fisiologia , Humanos , Lovastatina/farmacologia , Valores de ReferênciaRESUMO
Thymidine kinase (TK) gene expression is controlled in normal cells at both the transcriptional and posttranscriptional levels. Together, these regulatory systems mediate the 20-50-fold induction of TK mRNA observed as cells traverse the G1-S boundary of the cell cycle. Previously, we have reported that a "Yi" protein complex was observed to bind the mouse TK promoter in a cell cycle-dependent manner in nontransformed cells (Q-P. Dou, J. L. Fridovich-Keil, and A. B. Pardee, Proc. Natl. Acad. Sci. USA, 88: 1157-1161, 1991) and bound constitutively in transformed cells (D. W. Bradley, Q-P. Dou, J. L. Fridovich-Keil, and A. B. Pardee, Proc. Natl. Acad. Sci. USA, 87: 9310-9314, 1990). Nonetheless, TK mRNA levels in these cells continue to exhibit a marked S-specific induction (> 10 fold), raising the question: what is the status of TK promoter-mediated, as opposed to posttranscriptional, gene regulation in these transformed cells? To address this question, we have used cell synchrony experiments involving both transformed and nontransformed cells stably transfected with a TK promoter-beta-globin reporter gene construct. We have found that, in marked contrast to the tight regulation of reporter gene expression observed in nontransformed cells (J. L. Fridovich-Keil, J. M. Gudas, Q-P. Dou, I. Bouvard, and A. B. Pardee, Cell Growth & Differ., 2: 67-76, 1991), reporter gene expression in the transformed cells is constitutive and, therefore, closely parallels the presence of Yi DNA-binding activity. These data are fully consistent with other recently published observations concerning differential controls of TK transcriptional and posttranscriptional regulation (J. M. Gudas, J. L. Fridovich-Keil, and A. B. Pardee, Cell Growth & Regul., 4: 421-430, 1993) and support the hypothesis that, in transformed cells, endogenous TK is regulated predominantly at the posttranscriptional level.